Related Experiment Videos
Fotemustine in the treatment of brain primary tumors and metastases
Abstract:
Fotemustine is a new chloroethylnitrosourea characterized by the grafting of a phosphonoalanine group onto a nitrosourea radical. Clinical studies using fotemustine have been conducted in malignant glioma, brain metastasis of non-small cell lung cancer, and disseminated malignant melanoma. In recurrent malignant glioma, fotemustine has been used as a single agent: assessed by computed tomography scan, after 8 weeks, the objective response rate was 26.3% among 38 evaluable patients. Median duration of response was 33 weeks. The main toxicity was hematological (thrombocytopenia and leucopenia). A trial with high-dose fotemustine and autologous bone marrow rescue in newly diagnosed glioma was conducted in 26 patients, and 6 showed a partial response. The median overall survival was approximately 11 months. Myelosuppression was noted in all patients except 1, and other toxicity reported was central nervous system toxicity and epigastric pain. Combined with radiotherapy in 55 patients, a 29% response rate was observed, and this combination was well tolerated and easily manageable on an outpatient basis. Finally, fotemustine has been used intraarterially, with 10 objective responses observed among 26 evaluable patients. In brain metastases of non-small cell lung cancer, fotemustine proved to be active with a response rate of 16.7%. Combined with cisplatinum, fotemustine is still under study, but preliminary results are promising. In cerebral metastases of disseminated malignant melanoma, fotemustine has been evaluated in a total of 140 patients in the various studies: median response rate is 24.3%, ranging from 8.3% to 60.0%. Fotemustine appears to be a good candidate in the treatment of primary brain tumors and metastases.
Insights
Fotemustine, a novel nitrosourea, shows promise in treating brain tumors and metastases. Clinical trials indicate varying response rates and manageable toxicity in malignant glioma and melanoma brain metastases.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Fotemustine is a novel chloroethylnitrosourea derivative.
- It incorporates a phosphonoalanine group onto a nitrosourea core.
Purpose of the Study:
- To evaluate the efficacy and safety of fotemustine in treating primary brain tumors and brain metastases.
- To assess fotemustine's activity in malignant glioma, non-small cell lung cancer brain metastases, and malignant melanoma brain metastases.
Main Methods:
- Clinical studies involving fotemustine as a single agent and in combination therapies.
- Evaluation of response rates via computed tomography scans and assessment of toxicity profiles.
- Analysis of data from patients with recurrent and newly diagnosed glioma, non-small cell lung cancer metastases, and melanoma metastases.
Main Results:
- In recurrent malignant glioma, fotemustine demonstrated an objective response rate of 26.3% with a median response duration of 33 weeks.
- In brain metastases of non-small cell lung cancer, the response rate was 16.7%.
- In cerebral metastases of malignant melanoma, the median response rate was 24.3% across various studies.
Conclusions:
- Fotemustine exhibits activity in primary brain tumors and brain metastases.
- Hematological toxicity, particularly thrombocytopenia and leucopenia, is the main concern.
- Fotemustine is a potential therapeutic candidate for central nervous system malignancies and metastases.